Bayer/€BAYN

07:00
09:10
11:15
13:25
15:30
1D1W1MYTD1Y5YMAX

About Bayer

Bayer AG, operating under the ticker BAYN, is a global enterprise with core competencies in the life sciences fields of healthcare and agriculture. Founded in 1863, the company is headquartered in Leverkusen, Germany, and operates in several sectors, including Pharmaceuticals, Consumer Health, Crop Science, and Animal Health. Bayer is known for developing new molecules for use in innovative products and solutions to improve the health of humans, animals, and plants.

Ticker

€BAYN

Primary listing

XETRA

Industry

Pharmaceuticals

Employees

90,885

ISIN

DE000BAY0017

Bayer Metrics

BasicAdvanced
€26B
-
-€3.32
0.98
€0.11
0.42%

What the Analysts think about Bayer

Analyst ratings (Buy, Hold, Sell) for Bayer stock.

Bulls say / Bears say

Bayer's first-quarter adjusted EBITDA fell by 7.4% to €4.09 billion, surpassing market expectations of €3.75 billion, indicating resilience in its pharmaceutical segment. (reuters.com)
The U.S. FDA Commissioner reassured Bayer and other pharmaceutical executives of maintaining timely drug reviews, supporting the company's pipeline progression. (reuters.com)
Bayer's new drugs, Nubeqa and Kerendia, contributed significantly to U.S. sales, totaling €680 million in the first quarter, reflecting strong market acceptance. (reuters.com)
Bayer's shares hit a 20-year low after forecasting a decline in 2025 earnings due to weak agricultural markets, raising concerns about future profitability. (usnews.com)
The company is considering filing for bankruptcy for its Monsanto unit to manage ongoing Roundup litigation, highlighting significant legal and financial challenges. (reuters.com)
Bayer plans to exit the U.S. seed treatment equipment business and scale back German agriculture activities due to competitive pressures, indicating potential revenue declines. (reuters.com, reuters.com)
Data summarised monthly by Lightyear AI. Last updated on 5 Jun 2025.

Bayer Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Bayer Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.

Buy €BAYN

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs